$SENS
Senseonics Announces Partnership with Beyond Type 1
August 29, 2018
- Eversense CGM is now the Worldwide Presenting Sponsor of Type One Run
GERMANTOWN, Md., August 29, 2018 — Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, and Beyond Type 1, the world’s largest diabetes community on social media, today announced they are joining forces. Through an agreement making the Eversense® CGM the exclusive worldwide presenting sponsor of the Type One Run – a global network of running groups for people with type 1 diabetes – Senseonics will be partnering with Beyond Type 1 to build support, community, and awareness for those affected by type 1 diabetes through running.
Senseonics is the maker of the recently-approved Eversense® CGM System, the first long-term CGM system, featuring an implantable sensor that provides accurate continuous glucose readings for up to three months. Eversense provides a new alternative to the one- to two-week sensors of traditional CGM systems. It’s also ideal for active lifestyles because it features the first smart transmitter that can be removed and re-adhered without discarding a sensor.
“One of our core beliefs is to help people with diabetes confidently live with ease. The Eversense CGM System provides a new long-term CGM option for people who want to actively manage their diabetes,” said Mirasol Panlilio, Vice President and General Manager of Global Commercial at Senseonics. “The system fits well for athletes and runners who can enjoy the benefit of a high performing and secure sensor during physical activities. We are proud to partner with Beyond Type 1 and sponsor Type One Run’s more than 100 chapters worldwide to empower people with diabetes to live their healthiest lives.”
"Helping people impacted by Type 1 #LiveBeyond their diagnosis has been a core part of our energies since day one and the Eversense CGM system provides people with a management tool that aligns with our core values in a natural way,” said Sarah Lucas, CEO of Beyond Type 1. “We're thrilled to bring the energy and innovation of Senseonics to our community through this Type One Run partnership."
In the coming year, the Eversense sponsorship will also give participants at many of the Type One Run events a chance to explore the Ever Mobile Clinic. The Ever Mobile Clinic is a state-of-the art mobile educational facility sponsored by Senseonics that is custom-designed inside an expandable 18-wheeler to provide demonstrations of the Eversense CGM System as well as patient education via a video theater and two hands-on demonstration stations. In July, Senseonics kicked off the U.S. tour of the Ever Mobile Clinic, which is staffed with qualified trainers who provide education for patients interested in trying CGM to help them with the daily management of their diabetes.
About Senseonics and the Eversense Continuous Glucose Monitoring System
Senseonics Holdings, Inc. (NYSE American: SENS) is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense® CGM XL System received CE mark for up to 180 days of continuous use and is available in Europe. For more information on Senseonics, please visit www.senseonics.com.
The Eversense System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. Light, discreet, and comfortable to wear, the system's smart transmitter interprets glucose data from the sensor and sends it to the system's mobile application via Bluetooth, so patients can review their glucose data to help them make daily diabetes decisions.
http://www.senseonics.com/investor-relations/...08-29-2018
Senseonics Announces Partnership with Beyond Type 1
August 29, 2018
- Eversense CGM is now the Worldwide Presenting Sponsor of Type One Run
GERMANTOWN, Md., August 29, 2018 — Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, and Beyond Type 1, the world’s largest diabetes community on social media, today announced they are joining forces. Through an agreement making the Eversense® CGM the exclusive worldwide presenting sponsor of the Type One Run – a global network of running groups for people with type 1 diabetes – Senseonics will be partnering with Beyond Type 1 to build support, community, and awareness for those affected by type 1 diabetes through running.
Senseonics is the maker of the recently-approved Eversense® CGM System, the first long-term CGM system, featuring an implantable sensor that provides accurate continuous glucose readings for up to three months. Eversense provides a new alternative to the one- to two-week sensors of traditional CGM systems. It’s also ideal for active lifestyles because it features the first smart transmitter that can be removed and re-adhered without discarding a sensor.
“One of our core beliefs is to help people with diabetes confidently live with ease. The Eversense CGM System provides a new long-term CGM option for people who want to actively manage their diabetes,” said Mirasol Panlilio, Vice President and General Manager of Global Commercial at Senseonics. “The system fits well for athletes and runners who can enjoy the benefit of a high performing and secure sensor during physical activities. We are proud to partner with Beyond Type 1 and sponsor Type One Run’s more than 100 chapters worldwide to empower people with diabetes to live their healthiest lives.”
"Helping people impacted by Type 1 #LiveBeyond their diagnosis has been a core part of our energies since day one and the Eversense CGM system provides people with a management tool that aligns with our core values in a natural way,” said Sarah Lucas, CEO of Beyond Type 1. “We're thrilled to bring the energy and innovation of Senseonics to our community through this Type One Run partnership."
In the coming year, the Eversense sponsorship will also give participants at many of the Type One Run events a chance to explore the Ever Mobile Clinic. The Ever Mobile Clinic is a state-of-the art mobile educational facility sponsored by Senseonics that is custom-designed inside an expandable 18-wheeler to provide demonstrations of the Eversense CGM System as well as patient education via a video theater and two hands-on demonstration stations. In July, Senseonics kicked off the U.S. tour of the Ever Mobile Clinic, which is staffed with qualified trainers who provide education for patients interested in trying CGM to help them with the daily management of their diabetes.
About Senseonics and the Eversense Continuous Glucose Monitoring System
Senseonics Holdings, Inc. (NYSE American: SENS) is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense® CGM XL System received CE mark for up to 180 days of continuous use and is available in Europe. For more information on Senseonics, please visit www.senseonics.com.
The Eversense System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. Light, discreet, and comfortable to wear, the system's smart transmitter interprets glucose data from the sensor and sends it to the system's mobile application via Bluetooth, so patients can review their glucose data to help them make daily diabetes decisions.
http://www.senseonics.com/investor-relations/...08-29-2018
